Expression of CD105 and CD4+CD25+Foxp3+ Treg in peripheral blood of patients with non-small cell lung cancer undergoing Endostar plus chemotherapy and its significance

Objective: This study was designed to observe changes in peripheral blood CD105 and CD4(+)CD25(+)Foxp3(+) regulator T cells (Treg) in patients with non-small cell lung cancer (NSCLC) who underwent Endostar plus chemotherapy, and to evaluate the relationship between observation indexes and clinical therapeutic effects. Methods: A total of 57 NSCLC patients were included into this study and randomly divided into two groups: observation group (n= 2, Endostar combined with chemotherapy), and control group (n= 28, chemotherapy alone). Serum CD105 was detected by enzyme-linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) Treg was detected by fluorescence activated cell sorting (FACS). Results: The clinical effective rate was 72.41% (21/ 2) in the observation group and 42.86% (12/28) in the control group, and the difference in effective rate between these two groups was statistically significant (P<0.05). The levels of CD105 and CD4(+)CD25(+)Foxp3(+) Treg in peripheral blood were significantly lower in these two groups after treatment (P< 0.05). After treatment, the decrease in CD105 and CD4(+)CD25(+)Foxp3(+) Treg levels in peripheral blood was more significant in the observation group than that in the control group (P< 0.05). In the observation group, after four courses of chemotherapy, peripheral blood CD105 and CD4(+)CD25(+)Foxp3(+) Treg levels were positively correlated with the curative effect; while these were not correlated with the curative effect in the control group. Conclusion: Endostar combined with chemotherapy has a high therapeutic effect in the treatment of NSCLC, and CD105 and CD4(+)CD25(+)Foxp3(+) Treg may serve as new indicators for predicting its therapeutic effect.